Interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18

被引：2
作者：
Frederick, Peter J. [1 ]
Huh, Warner K. [1 ]
机构：
[1] Univ Alabama Birmingham, Div Gynecol Oncol, Dept Obstet Gynecol, Birmingham, AL 35249 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2008年 / 8卷 / 05期
关键词：
Cervarix; cervical cancer vaccine; human papillomavirus; HPV; 16; 18; PATRICIA;
D O I：
10.1586/14737140.8.5.701
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cervarix(TM) is a recombinant cervical cancer vaccine recently developed by GlaxoSmithKline Biologicals (Rixensart, Belgium). This vaccine is a prophylactic AS04 adjuvanted bivalent L1 virus-like-particle vaccine against human papillomavirus types 16 and 18, which together account for approximately 70% of cervical cancers worldwide. An interim analysis of a large, multicenter, Phase III trial being conducted by the Papilloma Trial against Cancer In young Adults (PATRICIA) study group to assess the efficacy of this vaccine was recently published in The Lancet. The purpose of this review is to summarize PATRICIA, with a specific focus on the results of the interim analysis, and discuss the impact and implications of the findings.
引用
收藏
页码：701 / 705
页数：5
相关论文
共 29 条
  • [1] Introducing HPV vaccine in developing countries - Key challenges and issues
    Agosti, Jan M.
    Goldie, Sue J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) : 1908 - 1910
  • [2] Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study
    Bjorge, T
    Engeland, A
    Luostarinen, T
    Mork, J
    Gislefoss, RE
    Jellum, E
    Koskela, P
    Lehtinen, M
    Pukkala, E
    Thoresen, SO
    Dillner, J
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (01) : 61 - 64
  • [3] Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands
    Boot, Hein J.
    Wallenburg, Iris
    de Melker, Hester E.
    Mangen, Marie-Jose M.
    Gerritsen, Annette A. M.
    van der Maas, Nicoline A.
    Berkhof, Johannes
    Meijer, Chris J. L. M.
    Kimman, Tieerd G.
    [J]. VACCINE, 2007, 25 (33) : 6245 - 6256
  • [4] Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
  • [5] Human papillomavirus types in invasive cervical cancer worldwide:: a meta-analysis
    Clifford, GM
    Smith, JS
    Plummer, M
    Muñoz, N
    Franceschi, S
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (01) : 63 - 73
  • [6] Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists
    Collins, Yvonne
    Einstein, Mark H.
    Gostout, Bobbie S.
    Herzog, Thomas J.
    Massad, L. Stewart
    Rader, Janet S.
    Wright, Jason
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 102 (03) : 552 - 562
  • [7] DELETE Y, 2007, EURO SURVEILL, V12
  • [8] Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1
  • [9] Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
    Giannini, Sandra L.
    Hanon, Emmanuel
    Moris, Philippe
    Van Mechelen, Marcelle
    Morel, Sandra
    Dessy, Francis
    Fourneau, Marc A.
    Colau, Brigitte
    Suzich, Joann
    Losonksy, Genevieve
    Martin, Marie-Therese
    Dubin, Gary
    Wettendorff, Martine A.
    [J]. VACCINE, 2006, 24 (33-34) : 5937 - 5949
  • [10] Gissmann L, 1992, Semin Cancer Biol, V3, P253
123